BetterLife Pharma Inc.
BETRF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BETRF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BETRF
BetterLife Pharma Inc. is a clinical-stage biotechnology company focused on developing therapies for neurological and psychiatric disorders, currently facing significant financial challenges and a going concern uncertainty.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Apr 30, 2019.
BetterLife Pharma Inc. is a clinical-stage biotechnology company focused on developing therapies for neurological and psychiatric disorders, currently facing significant financial challenges and a going concern uncertainty.
- BetterLife Pharma has incurred operating losses each year since inception in 2002, with a net loss of $3,621,884 for the year ended January 31, 2025 [sec · filed 2025-06-02].
- As of January 31, 2023, the company had an accumulated deficit of $112,186,681 [sec · filed 2023-05-31].
- The company's latest reported financials (as of 2019-04-30) show cash & equivalents of $0.0M, net income of -$1.9M, and negative shareholders' equity [sec].
- BetterLife Pharma has not generated any revenue since its inception and expects to incur substantial and increasing losses for the foreseeable future [sec · filed 2025-06-02].
- The company's ability to continue as a going concern is in doubt, as it may need to curtail or cease operations if additional funding is not obtained [sec · filed 2026-06-01].
What works
- The company has been actively reducing general and administrative expenses, including terminating investor relations contracts and reducing paid conferences, to minimize cash outflows [sec · filed 2026-06-01].
- BetterLife Pharma is focused on key research studies and strategic partnerships, which may provide future funding or development opportunities [sec · filed 2024-05-30].
What to weigh
- The company has a history of operating losses and negative cash flows from operations, with no revenue generated since inception [sec · filed 2025-06-02].
- There is substantial doubt about the company's ability to continue as a going concern, as it may not be able to secure additional funding on acceptable terms [sec · filed 2026-06-01].
- BetterLife Pharma faces significant regulatory and clinical risks, as it may never obtain regulatory approval for its proprietary substances or commence clinical testing [sec · filed 2026-06-01].
- The company's accumulated deficit of $112.2 million as of January 31, 2023, highlights the long-term financial strain and lack of profitability [sec · filed 2023-05-31].
From the filings
Quoted directly from source documents.
There is a material uncertainty about the company's ability to continue as a going concern.
“These events or conditions indicate that a material uncertainty exists that casts substantial doubt on our ability to continue as a going concern.”
SEC filings · June 1, 2026
The company has not generated any revenue since inception.
“We have not generated any revenue since our inception on June 10, 2002 and we have incurred operating and net losses in each year of our existence.”
SEC filings · June 2, 2025
The company had an accumulated deficit of $112,186,681 as of January 31, 2023.
“with an accumulated deficit of $112,186,681 at January 31, 2023”
SEC filings · May 31, 2023
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Material uncertainty exists that casts substantial doubt on the company's ability to continue as a going concern [sec · filed 2026-06-01].
- Lack of revenue and profitability — No revenue generated since inception in 2002; expects substantial and increasing losses [sec · filed 2025-06-02].
- Funding and liquidity risk — May not secure additional funding on acceptable terms; could be forced to curtail or cease operations [sec · filed 2026-06-01].
- Regulatory and clinical risk — No assurance of regulatory approval for proprietary substances; may never commence clinical testing [sec · filed 2026-06-01].
What to watch
- Ability to secure additional funding through strategic alliances or equity/debt offerings [sec · filed 2026-06-01].
- Progress in research and development activities, including any clinical testing or regulatory submissions [sec · filed 2026-06-01].
- Changes in operating expenses and cash burn rate as the company continues cost-reduction efforts [sec · filed 2026-06-01].
- Any updates on the company's going concern status or material changes in financial condition [sec · filed 2026-06-01].
Sources: SEC filings · Generated August 25, 2026 · How we verify sources →
Run BetterLife Pharma Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BetterLife Pharma Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
0.5 months
D/E 1.83 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Dec 2023Institutional holders
2
Total value held
$192
| Holder | Shares | Value |
|---|---|---|
| bartlett & co. wealth management llc | 4,000 | $192 |
| bartlett & co. llc | 4,000 | $0 |
Frequently asked questions
What is the AI investment thesis for BetterLife Pharma Inc.?
BetterLife Pharma Inc. is a clinical-stage biotechnology company focused on developing therapies for neurological and psychiatric disorders, currently facing significant financial challenges and a going concern uncertainty.
Who is the CEO of BetterLife Pharma Inc.?
Dr. Ahmad Doroudian Ph.D. is the chief executive officer of BetterLife Pharma Inc. (BETRF).
Where is BetterLife Pharma Inc. headquartered?
BetterLife Pharma Inc. (BETRF) is headquartered in Vancouver, BC, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.